Co-Authors
This is a "connection" page, showing publications co-authored by SUE-HWA LIN and SHI-MING TU.
Connection Strength
2.326
-
Prostate cancer stem cells. Clin Genitourin Cancer. 2012 Jun; 10(2):69-76.
Score: 0.412
-
Current trials using bone-targeting agents in prostate cancer. Cancer J. 2008 Jan-Feb; 14(1):35-9.
Score: 0.308
-
Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy? Cancers (Basel). 2022 Jan 27; 14(3).
Score: 0.204
-
Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors. Clin Genitourin Cancer. 2018 10; 16(5):325-327.
Score: 0.158
-
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43.
Score: 0.136
-
Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series. Case Rep Oncol Med. 2015; 2015:471861.
Score: 0.127
-
Variant prostate carcinoma and elevated serum CA-125. Can J Urol. 2014 Oct; 21(5):7442-8.
Score: 0.123
-
Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol. 2010 May; 8(5):341-51.
Score: 0.090
-
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36.
Score: 0.079
-
A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 04; 27(39):5195-203.
Score: 0.079
-
Biology and clinical management of prostate cancer bone metastasis. Front Biosci. 2007 May 01; 12:3273-86.
Score: 0.073
-
The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev. 2006 Dec; 25(4):601-9.
Score: 0.071
-
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer. 2006 Aug 01; 107(3):497-505.
Score: 0.070
-
Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005 Nov 01; 23(31):7904-10.
Score: 0.066
-
Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol. 2004 Jun; 203(2):688-95.
Score: 0.060
-
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2003 Aug 06; 95(15):1174-5; author reply 1175.
Score: 0.057
-
Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol. 2002 Aug; 3(8):508-13.
Score: 0.053
-
Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer. 2002 May 15; 94(10):2610-7.
Score: 0.052
-
Cabozantinib Reverses Renal Cell Carcinoma-mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo. Mol Cancer Ther. 2020 06; 19(6):1266-1278.
Score: 0.045
-
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999.
Score: 0.044
-
Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res. 2007 Jul; 5(7):675-84.
Score: 0.019